Literature DB >> 16046248

How to build an "active" patient? The work of AIDS associations in France.

Janine Barbot1.   

Abstract

"What is an "active" patient?" is a question that arises in most medicine and illness-related social science research. This article examines the normative work carried out by AIDS associations in France to define an "active" patient in healthcare and research. While the fight against AIDS is often presented as being homogenous, we look at the diversity of opinion between different associations (Aides, Act Up-Paris, Actions Traitements and Positifs). We find four different cases: the patient as manager of his illness, the empowerment of patients, the science-wise patient and the experimenter. Systematic comparison of these cases shows that these perceptions of the "active" patient, in terms of the same pathology, are based upon different ways of seeing: the nature of the relationships between the different types of knowledge of the illness (scientific knowledge, clinical knowledge, experience of the illness) and the distribution of roles and powers among the various actors in the healthcare system (the government, pharmaceutical companies, the medical profession, the patients). This article highlights the historical dynamics which allow us to have a better understanding of these differences, especially the major distinction between two generations of associations, which adopted different positions with regard to their public identity.

Entities:  

Mesh:

Year:  2005        PMID: 16046248     DOI: 10.1016/j.socscimed.2005.06.025

Source DB:  PubMed          Journal:  Soc Sci Med        ISSN: 0277-9536            Impact factor:   4.634


  14 in total

1.  Exploring the positions of German and Israeli patient organizations in the bioethical context of end-of-life policies.

Authors:  Aviad Raz; Isabella Jordan; Silke Schicktanz
Journal:  Health Care Anal       Date:  2014-06

2.  Involving patients in health technology funding decisions: stakeholder perspectives on processes used in Australia.

Authors:  Edilene Lopes; Jackie Street; Drew Carter; Tracy Merlin
Journal:  Health Expect       Date:  2015-02-21       Impact factor: 3.377

3.  Patients' lay expertise in chronic self-care: a case study in type 1 diabetes.

Authors:  Cristiano Storni
Journal:  Health Expect       Date:  2013-08-28       Impact factor: 3.377

4.  Activism, NGOs, and HIV Prevention in Postsocialist Poland: The Role of "Anti-Politics"

Authors:  Jill Owczarzak
Journal:  Hum Organ       Date:  2010

Review 5.  eHealth Literacy: Essential Skills for Consumer Health in a Networked World.

Authors:  Cameron D Norman; Harvey A Skinner
Journal:  J Med Internet Res       Date:  2006-06-16       Impact factor: 5.428

6.  Health activism and the logic of connective action. A case study of rare disease patient organisations.

Authors:  Stefania Vicari; Franco Cappai
Journal:  Inf Commun Soc       Date:  2016-03-21

7.  Assessing Patient Organization Participation in Health Policy: A Comparative Study in France and Italy.

Authors:  Kyriakos Souliotis; Eirini Agapidaki; Lily Evangelia Peppou; Chara Tzavara; Dimitrios Varvaras; Oreste Claudio Buonomo; Dominique Debiais; Stanimir Hasurdjiev; Francois Sarkozy
Journal:  Int J Health Policy Manag       Date:  2018-01-01

8.  HIV prevention: What have we learned from community experiences in concentrated epidemics?

Authors:  Bruno Spire; Isabelle de Zoysa; Hakima Himmich
Journal:  J Int AIDS Soc       Date:  2008-10-01       Impact factor: 5.396

9.  Do active patients seek higher quality prenatal care?: A panel data analysis from Nairobi, Kenya.

Authors:  Jessica Cohen; Ginger Golub; Margaret E Kruk; Margaret McConnell
Journal:  Prev Med       Date:  2016-09-22       Impact factor: 4.018

10.  How patients navigate the diagnostic ecosystem in a fragmented health system: a qualitative study from India.

Authors:  Vijayashree Yellapa; Narayanan Devadasan; Anja Krumeich; Nitika Pant Pai; Caroline Vadnais; Madhukar Pai; Nora Engel
Journal:  Glob Health Action       Date:  2017       Impact factor: 2.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.